Literature DB >> 16290783

Effect of pharmaceutically acceptable glycols on the stability of the liquid crystalline gels formed by Poloxamer 407 in water.

Rouja Ivanova1, Björn Lindman, Paschalis Alexandridis.   

Abstract

The ability of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) block copolymers (Poloxamers) to form "gels" (lyotropic liquid crystalline structures) in water is of interest to pharmaceutical applications. In such applications the presence of polar organic solvents is often desirable or required. The effect of such solvents on the stability of lyotropic liquid crystalline gels formed by PEO-PPO-PEO block copolymers was assessed by studying the phase behavior and structure in ternary isothermal (25 degrees C) systems of pharmaceutical interest consisting of Poloxamer 407 (EO(100)PO(70)EO(100)), water, and one of the following solvents (referred to here collectively as "glycols"): glycerol, propylene glycol, ethanol, polyethylene glycol 400, and glucose. Small-angle X-ray scattering was employed to establish the structure of the liquid crystals obtained and to determine their characteristic length scales. The stability range of the liquid crystalline gel phases in the systems studied was found to vary with the glycol type. For example, the micellar cubic structure can accommodate about 0.85:1 parts glucose per part water (in terms of weight) and up to as much as 5.5:1 parts propylene glycol per part water. A correlation between the glycol effects on the stability of the liquid crystalline phases and glycol physiochemical characteristics such as octanol/water partition coefficient or solubility parameter is proposed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 16290783     DOI: 10.1006/jcis.2002.8417

Source DB:  PubMed          Journal:  J Colloid Interface Sci        ISSN: 0021-9797            Impact factor:   8.128


  8 in total

1.  Development of tetracycline-serratiopeptidase-containing periodontal gel: formulation and preliminary clinical study.

Authors:  Manish Maheshwari; Gunjan Miglani; Amita Mali; Anant Paradkar; Shigeo Yamamura; Shivajirao Kadam
Journal:  AAPS PharmSciTech       Date:  2006-09-15       Impact factor: 3.246

2.  Preparation and characterization of pluronic-colloidal silicon dioxide composite particles as liquid crystal precursor.

Authors:  Manish Maheshwari; Anant Paradkar; Shigeo Yamamura; Shivajirao Kadam
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

3.  Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy.

Authors:  Ratnesh Jain; Swapna Nabar; Prajakta Dandekar; Vandana Patravale
Journal:  Pharm Res       Date:  2010-02-12       Impact factor: 4.200

4.  Pluronic micelles encapsulated curcumin manifests apoptotic cell death and inhibits pro-inflammatory cytokines in human breast adenocarcinoma cells.

Authors:  Foram U Vaidya; Rakesh Sharma; Sofiya Shaikh; Debes Ray; Vinod K Aswal; Chandramani Pathak
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-24

5.  Polymeric Micelles Enhance Mucosal Contact Time and Deposition of Fluocinolone Acetonide.

Authors:  Sucharat Limsitthichaikoon; Siriwat Soontaranon; Nuntachai Hanpramukkun; Kanjana Thumanu; Aroonsri Priprem
Journal:  Polymers (Basel)       Date:  2022-05-31       Impact factor: 4.967

6.  Formulation and characterization of echogenic lipid-Pluronic nanobubbles.

Authors:  Tianyi M Krupka; Luis Solorio; Robin E Wilson; Hanping Wu; Nami Azar; Agata A Exner
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

7.  Self-assembly, surface activity and structure of n-octyl-β-D-thioglucopyranoside in ethylene glycol-water mixtures.

Authors:  Cristóbal Carnero Ruiz; José Antonio Molina-Bolívar; José Manuel Hierrezuelo; Esperanza Liger
Journal:  Int J Mol Sci       Date:  2013-02-05       Impact factor: 5.923

8.  Single and dual drug release patterns from shellac wax-lutrol matrix tablets fabricated with fusion and molding techniques.

Authors:  T Phaechamud; C Choncheewa
Journal:  Indian J Pharm Sci       Date:  2015 Jan-Feb       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.